FDA approves first biosimilar for treatment of cancer

cancer treatment mvasi fda

On Sept. 14, the U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

Read More at FDA.gov


Please enter your comment!
Please enter your name here